Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
Certolizumab Combo Helps Curb RA Damage
Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
More Evidence Biomarkers Predict RA Relapse with DMARD Taper
2015 ACR Guideline for the Treatment of Rheumatoid Arthritis
Self-Monitoring of RA Treatment May Lead to Fewer Office Visits
Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients
High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
